Japan Tobacco applies to sell anti-HIV tablet in Japan
TOKYO Dec 6 (Reuters) - Japan Tobacco Inc said on Thursday it has applied to sell an anti-HIV drug treatment in Japan.
If approved by the Health Ministry, it would be the only once-daily single-tablet regimen for HIV infection in Japan, it said.
The drug contains JT's compound elvitegravir, which is used in Gilead Sciences Inc's Stribild regimen, approved by the U.S. Food and Drug Administration in August 2012.
- Boeing, SpaceX win contracts to build 'space taxis' for NASA
- iPhone comes out of a 'bygone era', reviewers hail bigger handset
- Polls show Scottish opponents of independence with slight lead ahead of vote |
- Wildfire rips through 150 homes in Northern California
- Fed could hint on rate-hike plans as it prepares for policy turn